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ABSTRACT 
Objective: The present research work aims to evaluate the hypolipidemic activity of arogyavardhini and zpter tablet in high fat diet (HFD) induced 
hyperlipidemia in wistar rats. 
Methods: Wistar rats were divided in 5 groups. The normal control group received standard pellet diet. The HFD group received HFD rich in 
cholesterol. The HFD+Arogyavardhini group received HFD rich in cholesterol along with Arogyavardhini treatment. The HFD+zpter group received 
HFD rich in cholesterol along with zpter treatment. The standard Control group received HFD rich in cholesterol and treatment with Atorvastatin. 
Serum Lipid profile estimation and histopathological estimations done at end treatment. Group means were compared with Analysis of Variance 
(ANOVA) followed by Tukey‘s post-hoc analysis (P<0.05).  
Result: HFD group shows significant (P<0.05) increase in total cholesterol (TC) levels (207.15 mg/dl) and triglyceride (TG) levels (223.83 mg/dl) 
when compared with standard pellet fed rats (TC=151.05 mg/dl and TG=164.67 mg/dl). Treatment with Arogyavardhini significantly (P<0.05) 
reduces the increased levels of TC (160.123 mg/dl) and TG (189.5 mg/dl) in hyperlipedimic rats. Treatment with Zpter significantly (P<0.05) 
reduces the increased levels of TC (163.89 mg/dl) and TG (193.167 mg/dl) in hyperlipedimic rats, which is comparable to standard treatment 
atorvastatin (TC= 155.81 mg/dl, TG=180.33 mg/dl). 
Conclusion: The observations in this study suggest that, herbal formulations arogyavardhini and zpter have the potential to overcome 
hyperlipidemia. 
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Hyperlipidemia is an illness, impairing the body in an unnoticeable 
way which is characterized by increased blood levels of lipids (fats) 
specifically cholesterol, cholesterol esters, phospholipids, plasma 
lipoproteins, low density lipoprotein (LDL) and it reduces high-
density lipoproteins (HDL). Hyperlipidemia hastens systemic 
atherosclerosis, which is considered as a major risk factor for 
causing atherosclerotic cardiovascular disease (ASCVD), like stroke, 
coronary artery disease, myocardial infarction and ischemic 
cardiomyopathy [1-4]. 
ASCVD is associated with major morbidity and mortality throughout 
the globe. Numerous reports indicate that there is a direct 
correlation exist between increased serum LDL and increased risk of 
cardiovascular diseases [5]. Several studies have reported that 
cholesterol-rich LDL and other apolipoproteins, like very low-
density lipoproteins (VLDL) and its intermediate forms like 
intermediate density lipoproteins (IDL) has a major role in the 
development of ASCVD [6].  
Cholesterol, a greasy substance, the main constituent of steroid 
hormones, bile salts and vitamin D. It is a constituent of cell 
membranes as well. It is both derived from the diet and synthesized 
within the body, specifically in the liver [7]. Raised serum 
cholesterol level predisposes to the risk of heart disease and stroke. 
Universally, a third of ischemic heart diseases are due to high 
cholesterol level. In general, increased cholesterol is responsible to 
cause 2.6 million deaths (4.5% of total) and 29.7 million disability 
adjusted life years (DALYS), or 2.0% of total DALYS. There is a 
positive correlation between increased total cholesterol and 
ischemic heart disease in the developed and developing world [8].  
Ayurved, 5,000-year-old system of medication is a holistic healing 
system that regards every individual as distinctive, and additionally 
takes under consideration the inherent relationship between the 
universe and individual. The aim of ayurveda medicine is to balance 
Tri-dosha (Vata, Pitta, and Kapha), the basic functional elements of 
the body to maintain the state of health and prevent illness through 
diet, nutrition, herbs, external therapies, meditation and daily and 
seasonal code of conduct or routines [9, 10]. 
There is no particular terminology for hyperlipidemia within the 
Ayurved. There are reports indicating the use of distinct terminology 
for hyperlipidemia, e. g. Rasagata Sneha Vriddhi (increase in lipids in 
plasma), Rasa-Raktagata Sneha Vriddhi (increase in the lipids in 
plasma and blood), Medovriddhi (generalized lipid increase), 
Medoroga or Medodosha (obesity), AAMA Medo Dhatu (ill-formed 
adipose tissue). Hyperlipidemia condition reflects its closeness to 
Asthayi Medo Dhatu Vriddhi (abnormal increase in circulating 
lipids). This overly raised lipids in circulation are AAMA in nature, 
resulting in further complexity [10, 11]. The abnormal MEDA (fats) 
developed because of an aberrant state of metabolite circulates 
within the body which gets accumulated, in turn manifested by 
flabbiness of the body parts like breasts, abdomen, etc. It causes 
hindrance to the flow of lymph and blood, inflicting lethargy, 
difficulty breathing, excess sleep, excessive perspiration, a foul body 
odor, and weakness, lack of stamina and loss of libido. Eventually, 
the surplus of fats progressively involved in DOSHA in the body and 
responsible for disorders
Recent hyperlipidemia treatment principles are based on reducing 
synthesis of cholesterol. Many drugs available today are statins [10]. 
 such as hypercholesterolemia, 
hypertension, diabetes mellitus, heart problems, joint disorders, and 
obesity. 
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Traditional treatment principles for hyperlipidemia aim to reduce
In house bred, healthy wistar rats at Shree Dhootapapeshwar 
Ayurvedic Research Foundation (Reg. No. of establishment-
136/PO/RcBi/S/99/CPCSEA) animal house facility were used for 
the study (CPCSEA protocol no. SDARF/PC/2013/03). At the starting 
of the experiment, the animals were acclimatized for 7 d in 
laboratory conditions. The animals were housed in sterile 
polypropylene cages. The room temperature was maintained at 
23±1 °C and animal room humidity was maintained at 55±5 %. 
Animals were provided with a 14 h light/10hr dark cycle. All the 
procedures conducted in the experiment were reviewed by and 
approved by the institutional animal ethics committee. 45 wistar 
rats of either sex treated with HFD rich in cholesterol for 30 d to 
ensure that enough number of animals with hyperlipidemia are 
available. Six animals within the control group were received 
standard pellet. After induction of hyperlipidemia, 24 wistar rats 
were taken from HFT fed animals and divided into four groups (HFD 
control, HFD+arogyavardhini group, HFD+zpter group, and standard 
control group). Animals in different groups will be treated as 
follows:  
Normal control (NC) group: A standard pellet diet offered to 
animals, over experimental period and was designated as NC group. 
HFD control group: Animals received a cholesterol-rich HFD over 
experimental period and was designated as a HFD control group. 
HFD+arogyavardhini group: Animals received a HFD rich in 
cholesterol over a period of 30 d and treated with arogyavardhini 
for the next 28 d. HFD continued during treatment. 
HFD+zpter group: Animals received a HFD rich in Cholesterol over 
a period of 30 d and treatment with zpter for the next 28 d. HFD 
continued during treatment. 
Standard control group: Animals received a HFD rich in 
Cholesterol and purified water for 30 d and treatment with 
atorvastatin as standard treatment for the 28 next days. HFD 
continued during treatment. 
The therapeutic dose equivalent to that of human therapeutic dose 
for Arogyavardhini and zpter was calculated. Therapeutic dose for 
Arogyavardhini in Rats was 18 mg/kg body weight/day and zpter 
was 49 mg/kg body weight/day. 
Initial body weights of animals were recorded. Body weight 
recording was done once every week during the experiment. 
Animals were treated for 28 d with respective group-specific agent.  
Serum biochemical analysis 
At the end of the experiment, blood was collected from rats in all 
groups by retro-orbital route. Animals were anesthetized at the time 
of blood collection. The serum lipid profile estimation (TC, TG, LDL, 
VLDL, and HDL) was carried out in automated chemistry analyzer 
(Randox Daytona, UK).  
Histopathological evaluation of liver 
Animals were humanely euthanized and liver tissue collected for 
histopathological evaluation. The tissue was thoroughly washed 
with normal saline solution and then tissue was fixed with 10% 
buffered formalin solution. After Fixation tissue was sliced into 4 
mm thick slices and kept into plastic cassettes. Further tissue was 
immersed in paraffin and cut into 5 micrometers thin sections using 
a rotary microtome. Then sections were warmed and stained using 
hematoxylin and eosin stain. Tissue sections were examined using 
light microscope. 
Statistical analysis 
Values were represented as mean±standard deviations (SD) for all 
groups. ANOVA, followed by Tukey‘s post-hoc test was done to 
compare the difference in group means and P<0.05 was taken as the 
level of significance. Non parametric comparison with Tukey‘s post-
hoc analysis was carried out using statistical software GraphPad 
Prism 8.00. 
RESULTS  
Effect of test formulation on body weight of wistar rats 
 
cholesterol biogenesis, which decreases blood levels of cholesterol. 
Statins generally act by inhibiting 3-hydroxy-3-methylgluataryl 
coenzyme a reductase. This enzyme helps in cholesterol 
biosynthesis. These drugs are most commonly used to control 
hyperlipidemia. Numerous studies have shown that, the treatment 
of Hyperlipidemia with statins, leads to chronic toxic effects which 
include carcinogenic, teratogenic, and mutagenic changes during 
longer duration of treatment. This has led to a search for more 
natural ways for controlling cholesterol levels [12]. 
Increased plasma levels of atorvastatin, lovastatin, and simvastatin 
may result in increased risk of severe myopathy or rhabdomyolysis 
[13]. 
So, in order to find solutions to these problems, healthcare 
researchers are looking for compounds with no or minimal side 
effects to treat hyperlipidemia. In this context, Ayurved system has 
the potential to treat a number of diseases with many advanced 
dosage forms comprised particularly of Shodhit (processed) 
mercury and the products contained thereof-Rasakalpa. With this 
background, the present research work aims to evaluate 
hypolipidemic activity of ayurvedic formulations arogyavardhini 
and zpter tablet in high fat diet (HFD) induced hyperlipidemia in 
wistar rats. 
MATERIALS AND METHODS 
Drugs and chemicals 
Arogyavardhini was procured from manufacturer shree 
dhootapapeshwar limited; mumbai, india, zpter was procured from 
manufacturer, solumiks herbaceuticals; mumbai, India atorvastatin 
and carboxyl methyl cellulose (CMC) were procured from local 
market. 
Arogyavardhini 
Arogyavardhini is an ayurveda herbo-mineral formulation, generally 
used for treating affectations of liver and spleen like jaundice, 
ajeerna (indigestion), durdharsha-kshutprapartini (Loss of appetite) 
and skin diseases. It consists of tamra bhasma (processed copper), 
shodhit (processed) mercury, triphala, amalaki (Emblica officinalis) 
fruit pericarp, chitraka (Plumbago zeylanica) root, katuka 
(Picrorhiza kurroa) rhizome, shodhit guggulu (processed 
Commiphora weightii) exudate, as major ingredients processed in 
nimba (Azadirachta indica) leaf juice. 
Zpter tablets is an ayurvedic formulation commonly indicated in 
the prevention and treating non-insulin dependent diabetes 
mellitus. Major contents of zpter tablet are asana (Pterocarpus 
marsupium), tvak (Cinnamomum zeylanicum), haridra (Curcuma 
longa), amalaki (Emblica officinalis) fruit pericarp and guduchi 
(Tinospora cordifolia). 
Preparation of doses, treatment, and duration 
The test formulations and standard drug were weighed and 
formulated with CMC (1% w/v) freshly on every day of dosing. 
Animals from control group were offered CMC throughout the 
treatment period. 
Experimental design 
During the period of hyperlipidemia induction and treatment, 
measurable changes in body weight were observed. At the end of 
the study, HFD treated rats showed significant (P<0.01) increase in 
body weight when compared with normal control rats. After 28 d 
treatment with test formulations, arogyavardhini (P<0.01) and 
zpter (P<0.05) treated groups of rats showed significantly 
decreased in the body weight when compared with HFD treated 
groups of rats (fig. 1). 
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Fig. 1: Effect of test formulations on body weight in wistar rats. All data expressed as group mean±SD Where NC-Normal Control, HFD High 
Fat Diet, ARG-Arogyavardhini, ATV-Atorvastatin. Where a P = Vs Normal Control, b P = Vs HFD Control and * = (P<0.05), ** = (P<0.01) 
 
Effect of test formulation on lipid profile of rats 
HFD group shows significant (P<0.01) increase in total 
cholesterol (TC) levels (Group Mean 207.15 mg/dl) when 
compared with standard pellet fed rats (group mean 151.05 
mg/dl). Treatment with Arogyavardhini (group Mean=160.123) 
and zpter (group mean = 163.89 mg/dl) significantly (P<0.05) 
reduces the increased level of TC in hyperlipedimic rats, which is 
comparable to standard treatment atorvastatin (group mean = 
155.81 mg/dl). 
HFD group shows significant (P<0.01) increase in triglyceride (TG) 
levels (group mean 223.83 mg/dl) when compared with standard 
pellet fed rats (group mean 164.67 mg/dl). Treatment with 
Arogyavardhini (group mean =189.5 mg/dl) and zpter (group mean 
= 193.16 mg/dl) significantly (P<0.05) reduces the increased level of 
TG in hyperlipedimic rats, which is comparable to standard 
treatment atorvastatin (group mean = 180.33 mg/dl). Fig. 2-A, 2-B). 
In this study, we found that, in HFD fed group, there was significant 
(p<0.05, P<0.01) increase in serum, LDL level (group mean=143.55 
mg/dl) and VLDL levels (group mean= 44.76 mg/dl), when 
compared with standard pellet treated rats (LDL group mean= 91.95 
mg/dl and VLDL group mean = 32.93 mg/dl). Treatment with test 
formulations arogyavardhini (LDL group mean= 96.05 mg/dl and 
VLDL group mean = 37.9 mg/dl) and zpter (LDL group mean= 99.93 
mg/dl and VLDL group mean = 38.63 mg/dl) significantly (p<0.05) 
reduces elevated levels of LDL and VLDL which are comparable to 
that of standard treatment atorvastatin (fig. 2-D and 2-E).  
In this study, HFD group rats show lower level of HDL (group 
mean=18.83 mg/dl as compare to Normal control group rats (group 
mean=26.67 mg/dl). Whereas, treatment with test formulation 
arogyavardhini (group mean=26.17 mg/dl) and zpter (group 
mean=25.33 mg/dl) and standard treatment (atorvastatin-28.17) 
significantly(p<0.05) elevates the decrease level of HDL as 
compared to HFD treated rats (fig. 2-C). 
 
 
Fig. 2: Effect of test formulations on lipid profile of rats, all data expressed in mean±Standard deviation (SD) Where NC-normal control, 
HFD high fat diet, ARG-arogyavardhini, and ATV-atorvastatin. Where a P = Vs Normal Control, b P = Vs HFD Control and * = (P<0.05), ** = 
(P<0.01), **** = (P<0.0001), n= 6, (A = effect of test formulation on triglyceride, B = effect of test formulation on total cholesterol, C = 
effect of Test formulation on HDL, D = effect of test formulation on LDL, E= effect of test formulation on VLDL) 
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Histology by hematoxylin and eosin (H and E) staining of rat liver section 
shows lipid droplet accumulation with the change in hepatocyte 
architecture in HFD fed control group of rats (fig. 3 B). Treatment with 
test formulations arogyavardhini and zpter group shows decrease in 
lipid droplet accumulation compared to HFD control group of rats and 
regaining of normal architecture (fig. 3-C, 3 D). 
  
 
Fig. 3: Histology of rats liver tissue (H and E staining) with 10 x magnification, where 3A= liver histology from NC (Normal Control) group, 
3 B HFD = Liver Histology from HFD control group, 3C HFD+ARG = Liver Histology from arogyavardhini treated group 3D HFD+ZPT = Liver 
Histology from Zpter treated group, 3E HFD+ATV = liver histology from atorvastatin treated group 
 
DISCUSSION 
Joris et al. reported that cholesterol alone cannot induce 
hyperlipidemia in Rats, so cholic acid is added with dietary 
cholesterol in order to induce hyperlipidemia [12]. The high fat diet 
administered in the present study includes cholic acid for effective 
hyperlipidemia induction [14, 15].  
The significant increase in serum TG and TC particularly, LDL and 
VLDL indicate induction of hyperlipidemia which further leads to 
the development of atherosclerosis. 
In humans, statin drugs are commonly used as cholesterol-lowering 
drugs. Therefore, the standard group was used to measure the 
effectiveness of the ayurvedic formulations in reducing plasma 
cholesterol levels when compared with statins [16, 17]. 
Findings in our study showed significant (p<0.05) increase in serum 
TG, TC, LDL and VLDL and significant (p<0.05) decrease in HDL 
group when compared with standard pellet fed rats. Findings in our 
study are Similar to those of previous reports, which confirms the 
induction of hyperlipidemia [15-19].  
Increase in serum LDL level causes cholesterol deposition in the 
arteries and aorta which further causes CHD as LDL involved in 
transport of cholesterol from the liver to end arteries [20, 21]. HDL, 
a lipoprotein synthesized in intestine and liver protect the system 
from the adverse effects of atherosclerosis [22].  
Treatment with test formulation (arogyavardhini and zpter) and 
standard treatment (atorvastatin) significantly (p<0.05) reduces the 
increased level of TG and cholesterol particularly LDL, VLDL in 
hyperlipidemic rats. Treatment with test formulation 
(Arogyavardhini and zpter) and standard treatment (Atorvastatin) 
significantly (p<0.05) elevates the decrease level of HDL in 
hyperlipedimic rats. The finding of our study represents similarities 
with the previous outcome [15]. 
The decrease in serum TC, LDL, TG, and increased HDL levels with 
arogyavardhini vati was reported previously in an efficacy study 
[23]. Guduchi (Tinospora cordifolia), which is major component of 
zpter Tablet has been reported to decrease triglyceride level in 
blood [24]. Extract of Curcuma longa which is component of zpter 
tablet was reported to shown a decrease in total plasma cholesterol 
and low-density lipoprotein cholesterol but increase in high-density 
lipoprotein cholesterol in rats fed with high-cholesterol diet [25]. 
Histopathological examination of liver tissues shown the decrease in 
fatty cytoplasm filled vacuolated cells in liver parenchyma with a 
decrease in hepatic necrosis and tissue architecture was coming 
back to normal. All the results obtained in our study are supported 
by previous findings.  
CONCLUSION 
The present investigation showed that arogyavardhini and zpter 
reduce the elevated level of serum TC, TG, LDL and VLDL and 
efficacies are comparable to that of standard treatment Atorvastatin. 
Treatment with test formulations arogyavardhini, zpter, and 
standard treatment atorvastatin prevent reduction of serum HDL 
level. Both test formulations arogyavardhini and zpter have the 
comparable hypolipidemic activity to standard treatment 
atorvastatin. From these findings indicate that Arogyavardhini and 
zpter have potential to treat Hyperlipidemia and in other associated 
disorders such as atherosclerosis. 
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